In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

B. Braun: Everywhere But Here

Executive Summary

Founded over 160 years ago, Germany-based B. Braun is a leading hospital supplier of medical supplies and products around the globe, combining a broad product and a strong service component. Pursuing a broad-based strategy that seeks to leverage its wide array of products, a la American Hospital Supply Corp., B. Braun officials nonetheless understand the importance of having state-of-the-art products in its many technology categories. Its US business has been less successful, raising the question why strong foreign suppliers often find it difficult to crack the US marketplace. But B. Braun is anything but a cautious, conservative, family-owned company, as its long history might suggest. From manufacturing to corporate culture, the company relentlessly pursues the latest and most up-to-date approaches.

You may also be interested in...



B. Braun's Bet on Balloons

Until now, B. Braun, one of the oldest players in cardiovascular devices, has been comfortable in its niche. B. Braun's cardiovascular business is actually made up of two units, one that makes products for interventional radiologists and surgeons in the peripheral field, the other on a range of devices used in interventional cardiology. But the investment the company is making in a new technology, drug-eluting balloons, could be disruptive, if not to interventional cardiology, at least to the cardiovascular device companies and none more so than B. Braun itself.

More Remdesivir Data, More Questions Linger

The latest data on the NIAID’s ACTT-1 study offers more help for clinicians trying to determine which coronavirus patients should receive remdesivir, but selection criteria – and supply – remain uncertain.

US FDA Office Of New Drugs Has New Deputy Director In Thanh Hai

The move means Hylton Joffe can focus exclusively on his role as director of the Office of Rare Diseases.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel